文献速递类风湿关节炎

风湿科医生治疗决策中患者偏好与经济因素的离散选择实验

Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists.
PubMed 文献 · Rheumatology (Oxford) · 2016-10-22

结果显示药物疗效相对贡献最大(44%),其次为药物成本(24%)、患者偏好(17%)和成本效果(14%)。医生决策更受绝对成本而非相对成本效果影响,且患者不喜欢某治疗时其偏好影响更大。

要点

  • 药物疗效是风湿科医生选择药物时贡献最大的属性(44%)。
  • 药物成本(24%)和患者偏好(17%)的贡献超过成本效果(14%)。
  • 严重但少见或罕见副作用风险对治疗选择影响很小(1%)。

核心结论

  • 风湿科医生在选择药物时,除药物疗效外,还考虑经济因素和患者偏好。
  • 决策更多受绝对成本影响而非相对成本效果,且患者不喜欢治疗时其偏好影响更大。

研究设计与样本

  • 假设患者为中度疾病活动度且两种合成DMARDs治疗失败的活动性RA患者,选择两种无标签药物治疗方案。

主要发现

  • 药物疗效对药物选择的相对贡献最强(44%),其次为药物成本(24%)、患者偏好(17%)和成本效果(14%)。
  • 严重但少见或罕见副作用风险对治疗选择仅起次要作用(1%)。
  • 患者偏好当患者不喜欢 proposed 治疗时最相关。

关键数值与推荐

  • 属性包括疗效(DAS28改善水平和达到状态)、安全性(严重不良事件概率)、患者偏好(同意程度)、年药物成本和成本效果(增量成本效果比),各设三个水平。
  • 高效实验设计生成14个治疗选择,采用随机参数logit模型估计属性相对重要性。

临床怎么用

  • 临床决策中应关注药物绝对成本及患者对治疗的负面偏好。
  • 严重但少见或罕见副作用风险在药物选择中权重较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate to what extent rheumatologists consider economic aspects and patients' preferences when choosing drug treatments in patients with active RA. METHODS: In a discrete choice experiment, rheumatologists were asked to choose between two unlabelled drug treatment options for a hypothetical RA patient with moderate disease activity who failed two synthetic DMARDs. Attributes and levels of drug treatments were selected based on existing literature, rheumatologists' opinion and expert consensus. This resulted in five attributes each described by three levels: efficacy (level of improvement and achieved state on DAS28), safety (probability of a serious adverse event), patients' preference (level of agreement), annual medication costs and cost-effectiveness (incremental cost-effectiveness ratio). An efficient experimental design generated 14 treatment choices and a random parameter logit model estimated the relative importance of attributes. RESULTS: Sixty-three rheumatologists from the Netherlands contributed to the analysis; 44% were female and mean (sd) age was 49 (8) years. Drug efficacy had the strongest relative contribution to the drug choice (44%) followed by medication costs (24%), patients' preference (17%) and cost-effectiveness (14%). Patients' preferences were most relevant when patients disliked a proposed treatment. The risk of serious but uncommon or rare side effects only played a minor role in the treatment choice (1%). CONCLUSION: In addition to drug efficacy, rheumatologists account for economic aspects and for patients' preferences when deciding on drugs. Decisions are more influenced by absolute costs than relative cost-effectiveness and by patients' disliking as opposed to favouring the treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hifinger M, Hiligsmann M, Ramiro S, et al. Patients' preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists. Rheumatology (Oxford). 2016. PMID: 28028156. doi:10.1093/rheumatology/kew328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。